We are very sorry but it looks like you are using an outdated browser. We strongly recommend updating to a modern browser.
More information about your browser and how to update

Biotie Therapies GmbH

Biotie is a drug discovery and development company focused on central nervous system and inflammatory diseases. It has a broad range of innovative small molecule and biological drug candidates at different stages of clinical and pre-clinical development. Biotie’s products address diseases with high unmet medical need and significant market potential, including addiction and psychotic disorders, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary disease (COPD). The most advanced product, nalmefene for alcohol dependence, is currently in phase III clinical development by licensing partner H. Lundbeck A/S.
The commercial value of the pipeline has been demonstrated through existing alliances with top-tier global pharmaceutical companies such as Lundbeck, Roche and Wyeth. Biotie has operations in Turku, Finland and Radebeul, Germany.

Details


Address:
Biotie Therapies GmbH

Meissner Strasse 191
01445 Radebeul
Germany
Field of Activity:
Other Activities
Expansion:
international
Website:
Number of employess:
11-50
Founding year:
2002